ASH 2025 LBA BRUIN-CLL 313 Update: Pirtobrutinib vs Bendamustine/Rituximab in 1L CLL
Two Onc Docs
00:00
CLL treatment landscape
Kareen outlines BTK inhibitors, venetoclax regimens, TLS risk, and considerations for TP53/17p disease.
Play episode from 03:30
Transcript
